Generic Aggrastat Availability
Last updated on Jan 11, 2023.
AGGRASTAT (tirofiban hydrochloride - injectable;injection)
Approval date: May 14, 1998
Strength(s): EQ 12.5MG BASE/50ML (EQ 0.25MG BASE/ML) (discontinued)
AGGRASTAT (tirofiban hydrochloride - solution;injection)
Approval date: August 31, 2016
Strength(s): EQ 3.75MG BASE/15ML (EQ 0.25MG BASE/ML) [RLD]
AGGRASTAT (tirofiban hydrochloride - solution;intravenous)
Approval date: May 14, 1998
Strength(s): EQ 25MG BASE/500ML (EQ 0.05MG BASE/ML) (discontinued)
Approval date: April 20, 2000
Strength(s): EQ 12.5MG BASE/250ML (EQ 0.05MG BASE/ML) [RLD] [AP]
Approval date: May 17, 2002
Strength(s): EQ 5MG BASE/100ML (EQ 0.05MG BASE/ML) [RLD]
Has a generic version of Aggrastat been approved?
A generic version of Aggrastat has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Aggrastat and have been approved by the FDA:
Manufacturer: GLAND PHARMA LTD
Approval date: April 8, 2021
Strength(s): EQ 12.5MG BASE/250ML (EQ 0.05MG BASE/ML) [AP]
Note: No generic formulation of the following products are available.
- tirofiban hydrochloride - injectable;injection
- tirofiban hydrochloride - solution;injection
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Aggrastat. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Method for inhibiting platelet aggregation
Issued: August 3, 2004
Inventor(s): Peter M.; DiBattiste & David; Schneider
Assignee(s): Artery LLC
A method for inhibiting platelet aggregation in a patient in need thereof, comprising 1) administering to the patient a bolus injection of an active drug, in an amount of about 25 &mgr;g/kg, and 2) administering to the patient, after the bolus injection, an intravenous infusion for a period of between about 12 hours and about 72 hours, of the active drug, in an amount of about 0.15 &mgr;g/kg/min, wherein the active drug is tirofiban or a salt thereof.
Patent expiration dates:
- May 1, 2023✓
- May 1, 2023
More about Aggrastat (tirofiban)
- Check interactions
- Pricing & coupons
- Side effects
- Dosage information
- During pregnancy
- Drug class: glycoprotein platelet inhibitors
- En español
Related treatment guides
|Drug Patent||A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.|
|Drug Exclusivity||Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.|
|RLD||A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.|
|AP||Injectable aqueous solutions and, in certain instances, intravenous non-aqueous solutions. It should be noted that even though injectable (parenteral) products under a specific listing may be evaluated as therapeutically equivalent, there may be important differences among the products in the general category, Injectable; Injection. For example, some injectable products that are rated therapeutically equivalent are labeled for different routes of administration. In addition, some products evaluated as therapeutically equivalent may have different preservatives or no preservatives at all. Injectable products available as dry powders for reconstitution, concentrated sterile solutions for dilution, or sterile solutions ready for injection are pharmaceutical alternative drug products. They are not rated as therapeutically equivalent (AP) to each other even if these pharmaceutical alternative drug products are designed to produce the same concentration prior to injection and are similarly labeled. Consistent with accepted professional practice, it is the responsibility of the prescriber, dispenser, or individual administering the product to be familiar with a product's labeling to assure that it is given only by the route(s) of administration stated in the labeling.|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.